Illumina, Inc.

Illumina, Inc. is a genomics technology company headquartered in San Diego, California, founded in 1998. Its shares trade on Nasdaq under the ticker ILMN, and it is a member of the S&P 500 index. The company develops sequencing technologies that read the genetic information in DNA and RNA.

Its income structure rests on three legs. The first is sequencing systems such as the NovaSeq and NextSeq. The second is consumables, such as the reagents and flow cells used in every run on these instruments; continuing consumables sales after an instrument is installed underpin the business model. The third is software and analysis services that process the data. Customers include universities, research institutes, drug companies and clinical laboratories. GRAIL, which focuses on early cancer detection, separated from Illumina in 2024 and became a separate company.

Those following Illumina stock typically track research institution budgets, the spread of clinical genomic testing, competing sequencing technologies and trade policies. On the ILMN page at Lzzo.com the price is shown in US dollars, and a historical price chart and technical indicators appear on the same page.